NY-ESTEE-LAUDER
18.6.2020 15:41:12 CEST | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) announced that Michelle Freyre will join The Estée Lauder Companies as Senior Vice President, Global General Manager, Clinique, effective July 1, 2020. She will report to John Demsey, Executive Group President, The Estée Lauder Companies (ELC), and will succeed Jane Lauder, who has been appointed Executive Vice President, Enterprise Marketing and Chief Data Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005556/en/
In her new role leading Clinique, Michelle will be responsible for guiding the brand’s overall strategic vision, including innovation, product development and marketing, and all facets of consumer and digital engagement. She will partner closely with members of the global Clinique leadership team to continue brand momentum by driving consumer relevance globally and connecting emotionally with consumers throughout their beauty journey. Michelle and her team will also work to imagine the future of the retail experience, including Clinical Reality, Virtual Selling and High Touch services.
Michelle joins The Estée Lauder Companies from Johnson & Johnson, where she had an impressive 20-year career holding various leadership roles within its Consumer Health Products division, most recently serving as President, U.S. Beauty. In this role, she was responsible for the company’s portfolio of beauty brands at the time, including Neutrogena, Aveeno, Clean & Clear and RoC, and led the successful performance of many brands. Notably, she successfully transformed the image of Johnson & Johnson Beauty with a fully re-imagined Celebrity Talent & Influencer Strategy, diversifying the talent portfolio to reflect a more integrated approach.
“Michelle is a dynamic leader with deep experience across beauty, including marketing, innovation, sales, consumer engagement and strategic growth,” said Mr. Demsey. “She is particularly adept at finding new and innovative ways to fuel growth by exceeding consumer expectations and pushing the boundaries of possibility. She is a wonderful fit for Clinique, and I am thrilled to welcome her to the brand.”
Jane Lauder added, “I could not be happier that Michelle is joining Clinique. She has a tremendous track record of driving successful beauty brands, and her passion for surprising and delighting the global consumer is unparalleled. The Clinique team is lucky to have her as a leader, and I know the brand will be in wonderful hands with her at the helm.”
Prior to her role as President, U.S. Beauty, she served as the General Manager of Neutrogena, the largest brand within Johnson & Johnson’s Consumer division, and as the leader of the company’s Los Angeles campus. During her tenure, she strengthened brand leadership positions in facial care and sun care by focusing on core hero products and franchises and disruptive innovation across categories.
Michelle is passionate about talent development and has a proven track record of fostering workplaces that embrace inclusion and diversity, strengthening the talent pipeline at Johnson & Johnson with high-potential, diverse leaders. She has received several awards and honors in recognition of her exceptional career, including being named to Fortune’s 2018 “50 Most Powerful Latinas in Business.” Additionally, she sits on the Board of Directors of Cynosure, LLC, and is a founding member of CHIEF, a private network designed to accelerate women in business and support women leaders.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005556/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom